Phase II study of Carboplatin plus nab-Paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease
- Conditions
- Advanced non-small cell lung cancer with interstitial lung disease
- Registration Number
- JPRN-UMIN000012989
- Lead Sponsor
- Kanagawa Cardiovascular and Respiratory Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Not provided
1) Synchronous or metachronous active double malignancies 2) Other lung disease, including infection, pneumoconiosis, drug-induced pneumonitis, sarcoidosis, and collagen vasucular disease 3) With symptomatic central nervous system metastases 4) Hypersensitvity to platinum or paclitaxel 5) Receiving systemic treatment with steroid or immunosuppressant 6) Positive for hepatitis B surface antigen 7) Women who are currently pregnant or will not be compliant with a medically approved contraceptive regimen during the treatment period and lactating women. 8) Men who will not be compliant with a contraceptive regimen during and for the treatment period 9) Psychotic disorder which prevent the patient from giving informed consent 10) Other criteria judged by the investigator to make a patient unsuitable for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exacerbation-free rate of ILD at 28 days after protocol treatment
- Secondary Outcome Measures
Name Time Method Response rate, Progression-free survival, Overall survival, Exacerbation-free rate of ILD, Toxicities